<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02214563</url>
  </required_header>
  <id_info>
    <org_study_id>CKDR-003</org_study_id>
    <nct_id>NCT02214563</nct_id>
  </id_info>
  <brief_title>Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients</brief_title>
  <acronym>CHAMBER</acronym>
  <official_title>Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients (CHAMBER): A Multicenter, Double-blind, Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yoshiharu Tsubakihara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Japan Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Molecular Physiological Chemistry Laboratory, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Obi clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Higashikouri Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nishi clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Futaba clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Akebono clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Osaka University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether cholecalciferol supplementation decrease
      the blood concentrations of hepcidin-25 in hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 4 arms in this study: (1) Thrice-weekly cholecalciferol supplementation (3,000 IU),
      (2) Monthly cholecalciferol supplementation (equivalent to 9,000/week), (3) Thrice-weekly
      placebo, and (4) Monthly placebo. The primary analyses will be done regarding 2
      cholecalciferol groups and 2 placebo groups as one group each, and we will evaluate the
      effect of cholecalciferol regardless of the supplementation regimen. As the secondary
      analyses, we will examine if there is any difference between thrice-weekly and once-monthly
      supplementation regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentrations of hepcidin-25</measure>
    <time_frame>The 3rd month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentrations of hepcidin-25</measure>
    <time_frame>The 3rd day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of hepcidin-25</measure>
    <time_frame>The 6th month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change of erythropoietin resistance index (ERI) overtime</measure>
    <time_frame>Up to the 6th month</time_frame>
    <description>ERI = Average weekly dose of erythropoiesis-stimulating agents (ESA) over prior 4 weeks / post-dialysis body weight (kg) / Hb (g/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of 1,25-dihydroxyvitamin D, bone specific alkaline phosphatase (BAP), and tartrate-resistant acid phosphatase (TRAcP) 5b</measure>
    <time_frame>The 3rd month</time_frame>
    <description>In the secondary analysis, we will adjust baseline concentrations when comparing the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of 1,25-dihydroxyvitamin D, bone specific alkaline phosphatase (BAP), and tartrate-resistant acid phosphatase (TRAcP) 5b</measure>
    <time_frame>The 6th month</time_frame>
    <description>In the secondary analysis, we will adjust baseline concentrations when comparing the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of high-sensitive C reactive protein (CRP), interleukin (IL)-6, and tumor necrosis factor (TNF)-alpha</measure>
    <time_frame>The 3rd day</time_frame>
    <description>In the secondary analysis, we will adjust baseline concentrations when comparing the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of high-sensitive C reactive protein (CRP), interleukin (IL)-6, and tumor necrosis factor (TNF)-alpha</measure>
    <time_frame>The 3rd month</time_frame>
    <description>In the secondary analysis, we will adjust baseline concentrations when comparing the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of high-sensitive C reactive protein (CRP), interleukin (IL)-6, and tumor necrosis factor (TNF)-alpha</measure>
    <time_frame>The 6th month</time_frame>
    <description>In the secondary analysis, we will adjust baseline concentrations when comparing the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of calcium, phosphate, and intact parathyroid hormone overtime</measure>
    <time_frame>Up to the 6th month</time_frame>
    <description>In the secondary analysis, we will adjust baseline concentrations when comparing the groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hypercalcemia</measure>
    <time_frame>Up to the 6th month</time_frame>
    <description>&gt;=10.5 mg/dL of albumin corrected calcium</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Anemia</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Bone Diseases, Metabolic</condition>
  <arm_group>
    <arm_group_label>Thrice-weekly cholecalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capsule containing 3,000 IU of cholecalciferol will be given at the end of each hemodialysis session. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monthly cholecalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capsules containing a dose equivalent to 9,000 IU/week will be given at the end of the first hemodialysis session in the 3rd week of each month. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thrice-weekly placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olive oil coated by soft capsule made of gelatin and glycerin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monthly placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olive oil coated by soft capsule made of gelatin and glycerin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.</description>
    <arm_group_label>Thrice-weekly cholecalciferol</arm_group_label>
    <arm_group_label>Monthly cholecalciferol</arm_group_label>
    <other_name>vitamin D</other_name>
    <other_name>vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Olive oil</intervention_name>
    <arm_group_label>Thrice-weekly placebo</arm_group_label>
    <arm_group_label>Monthly placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with end-stage renal disease receiving thrice-weekly maintenance hemodialysis

          -  On treatment with erythropoietin stimulating agent

          -  With written informed consent

        Exclusion Criteria:

          -  On treatment with epoetin beta pegol as ESA

          -  On supplementation with native vitamin D

          -  Hypercalcemia (&gt;=10.5 mg/dL of corrected serum calcium)

          -  On treatment with intravenous iron agents

          -  Judged as ineligible to the randomized study by the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshiharu Tsubakihara, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hyogo Prefectural Nishinomiya Hospital</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>662-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higashikouri hospital</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akebono clinic</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-4112</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obi clinic</name>
      <address>
        <city>Osaka</city>
        <zip>543-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishi clinic</name>
      <address>
        <city>Osaka</city>
        <zip>552-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Futaba clinic</name>
      <address>
        <city>Osaka</city>
        <zip>559-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24204002</url>
    <description>Link to the report which showed the negative effect of vitamin D on blood hepcidin-25 concentration in human subjects</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2014</study_first_submitted>
  <study_first_submitted_qc>August 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2014</study_first_posted>
  <last_update_submitted>September 24, 2017</last_update_submitted>
  <last_update_submitted_qc>September 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Osaka University</investigator_affiliation>
    <investigator_full_name>Yoshiharu Tsubakihara</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>Hepcidins</keyword>
  <keyword>Renal Dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

